Table 3 Effects of DHS and DMS on muscarine-induced reductions in luminal airway area in PCLS from M2 R-KO and theircorresponding wild-type mice. The number of experiments (lungs/slices), mean airway diameter in μm, and the muscarine-induced constriction in luminal airway area (expressed in %) determined after 1 min (1) and 15 min (2) after stimulation with muscarine and 1 min (3) and 15 min (4) after stimulation with muscarine in combination with DHS or DMS (both 10-6 M or 10-8 M) are shown. In all experiments, the muscarine concentration was 10-6 M. The initial phase (1 vs 3) and the sustained phase (2 vs 4) of constriction were reduced in the presence of DHS or DMS. Data are given as means ± S.E.M.
M2R-wt Lungs /slices | Diameter [μm] | Area [%] 1 | Area [%] 2 | Area [%] 3 | Area [%] 4 | p (1 vs. 3) | p (2 vs. 4) |
|---|---|---|---|---|---|---|---|
6/7 | 208 ± 9 | Mus | Mus/DHS 10-6 M | p ≤ 0.05 | p ≤ 0.05 | ||
35 ± 9 | 32 ± 9 | 77 ± 11 | 52 ± 11 | ||||
7/8 | 213 ± 8 | Mus | Mus/DHS 10-8 M | n.s. p = 0.078 | p ≤ 0.05 | ||
46 ± 6 | 45 ± 12 | 61 ± 9 | 60 ± 9 | ||||
5/5 | 202 ± 17 | Mus | Mus/DMS 10-6 M | p ≤ 0.05 | p ≤ 0.05 | ||
40 ± 10 | 42 ± 9 | 72 ± 9 | 66 ± 10 | ||||
7/7 | 217 ± 8 | Mus | Mus/DMS 10-8 M | p ≤ 0.05 | p ≤ 0.05 | ||
54 ± 10 | 41 ± 9 | 69 ± 10 | 60 ± 10 | ||||
M2R-KO | |||||||
6/6 | 210 ± 8 | Mus | Mus/DHS 10-6 M | p ≤ 0.05 | p ≤ 0.05 | ||
50 ± 11 | 54 ± 11 | 79 ± 7 | 82 ± 7 | ||||
7/7 | 194 ± 9 | Mus | Mus/DHS 10-8 M | p ≤ 0.05 | p ≤ 0.05 | ||
44 ± 10 | 48 ± 8 | 74 ± 8 | 74 ± 7 | ||||
7/8 | 218 ± 8 | Mus | Mus/DMS 10-6 M | p ≤ 0.05 | p ≤ 0.05 | ||
56 ± 8 | 62 ± 7 | 83 ± 6 | 79 ± 6 | ||||
7/7 | 189 ± 9 | Mus | Mus/DMS 10-8 M | p ≤ 0.05 | p ≤ 0.05 | ||
43 ± 13 | 51 ± 11 | 71 ± 9 | 73 ± 9 | ||||